Open AccessTucatinib (Tukysa)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.202
Subject(s) - trastuzumab emtansine , pertuzumab , trastuzumab , capecitabine , medicine , human epidermal growth factor receptor 2 , oncology , cish , metastatic breast cancer , breast cancer , cancer , biology , in situ hybridization , biochemistry , gene expression , colorectal cancer , gene
CADTH recommends that Tukysa should be reimbursed by public drug plans for the treatment of patients with advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or is metastatic, including patients with brain metastases, if certain conditions are met.
Tukysa should only be reimbursed if prescribed in combination with trastuzumab-capecitabine and the cost of Tukysa is reduced.
Tukysa should only be covered to treat patients who have been previously treated for HER2-positive breast cancer with trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1).